Table 2 Baseline information of HNSC patients.
Characteristics | Low expression of ETV4 | High expression of ETV4 | P value |
|---|---|---|---|
n | 252 | 252 | |
Age, n (%) | 0.448 | ||
<= 60 | 119 (23.7%) | 128 (25.4%) | |
> 60 | 132 (26.2%) | 124 (24.7%) | |
Gender, n (%) | 0.002 | ||
Female | 82 (16.3%) | 52 (10.3%) | |
Male | 170 (33.7%) | 200 (39.7%) | |
Pathologic T stage, n (%) | 0.060 | ||
T1 | 28 (6.2%) | 17 (3.8%) | |
T2 | 74 (16.5%) | 61 (13.6%) | |
T3 | 40 (8.9%) | 56 (12.5%) | |
T4 | 80 (17.9%) | 92 (20.5%) | |
Pathologic N stage, n (%) | 0.001 | ||
N0 | 101 (24.6%) | 70 (17%) | |
N1 | 29 (7.1%) | 37 (9%) | |
N2 | 68 (16.5%) | 99 (24.1%) | |
N3 | 1 (0.2%) | 6 (1.5%) | |
Pathologic M stage, n (%) | 0.481 | ||
M0 | 98 (51.9%) | 90 (47.6%) | |
M1 | 0 (0%) | 1 (0.5%) | |
Pathologic stage, n (%) | 0.054 | ||
Stage I | 18 (4.1%) | 7 (1.6%) | |
Stage II | 39 (8.9%) | 31 (7.1%) | |
Stage III | 38 (8.7%) | 41 (9.4%) | |
Stage IV | 120 (27.5%) | 142 (32.6%) | |
Radiation therapy, n (%) | 0.051 | ||
No | 88 (19.9%) | 67 (15.2%) | |
Yes | 135 (30.5%) | 152 (34.4%) | |
OS event, n (%) | 0.048 | ||
Alive | 154 (30.6%) | 132 (26.2%) | |
Dead | 98 (19.4%) | 120 (23.8%) |
